BSSP (Cantech Holding) Debt-to-Equity: -0.44 (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantech Holding Debt-to-Equity?

Cantech Holding BSSP -99.50% Debt-to-Equity is -0.44 as of Sep. 2015.

Cantech Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.35 Mil. Cantech Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.03 Mil. Cantech Holding's Total Stockholders Equity for the quarter that ended in Sep. 2015 was $-0.86 Mil. Cantech Holding's debt to equity for the quarter that ended in Sep. 2015 was -0.44.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cantech Holding's Debt-to-Equity or its related term are showing as below:

BSSP's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.155
* Ranked among companies with meaningful Debt-to-Equity only.

Cantech Holding  (OTCPK:BSSP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cantech Holding Debt-to-Equity Related Terms

Cantech Holding Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cantech Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantech Holding Debt-to-Equity Chart

Cantech Holding Annual Data
Trend Dec11 Dec12 Dec13 Dec14
Debt-to-Equity
-1.00 -0.95 -0.93 -0.61

Cantech Holding Quarterly Data
Sep10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -0.61 -0.57 -0.38 -0.44

BSSP vs HSTC, NTRR, TLOG: Debt-to-Equity Comparison

For the Biotechnology subindustry, Cantech Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantech Holding Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantech Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cantech Holding's Debt-to-Equity falls into.


Cantech Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cantech Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.249 + 0.001) / -0.408
=-0.61

Cantech Holding's Debt to Equity Ratio for the quarter that ended in Sep. 2015 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.351 + 0.026) / -0.862
=-0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.44 mean?
Cantech Holding (BSSP) has a Debt-to-Equity of -0.44 as of Sep. 2015. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cantech Holding and its competitors.
Is Cantech Holding's Debt-to-Equity too high?
Cantech Holding's current Debt-to-Equity is -0.44.
How does Cantech Holding's Debt-to-Equity compare to HSTC and NTRR?
Cantech Holding's Debt-to-Equity of -0.44 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cantech Holding and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantech Holding's current Debt-to-Equity is -0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantech Holding stock overvalued right now?
Cantech Holding (BSSP) has a current Debt-to-Equity of -0.44. The current Debt-to-Equity is -0.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cantech Holding (BSSP), the current Debt-to-Equity is -0.44 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantech Holding Business Description

Address 120 W Pomona Avenue, Monrovia, CA, USA, 91016
Cantech Holding Inc is a development stage immunotherapeutic-based technology company. Principally, it is focused on commercialization of its proprietary proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsine Fraction (IPF) is a therapeutic platform technology that can be used to facilitate varieties of applications. The company's product consists of IMMUNE-THERAPEUTIC PROTEIN which is a therapeutic protein isolated from porsine pepsin and is irreversible, modified, and fractionated to the sequence IPF.